COVID-19 is no longer a global health emergency, but it isn’t gone. The WHO officially ended its emergency declaration in May 2023, and the virus has settled into a pattern more like seasonal flu: always circulating, occasionally surging, and still capable of causing serious illness in vulnerable people. The short answer is that the pandemic phase is over, but COVID itself is not.
What “Over” Actually Means
When epidemiologists talk about a disease being “over,” they distinguish between a pandemic and an endemic disease. A pandemic means explosive, disruptive spread that overwhelms health systems. Endemic means the virus has a constant presence without those massive surges. By that standard, COVID has clearly crossed the line. As Bill Hanage, an epidemiologist at Harvard’s School of Public Health, put it: “We’re definitely there.”
But endemic doesn’t mean harmless. Malaria is endemic. Tuberculosis is endemic. The word simply describes a pattern of ongoing circulation, not a judgment about severity. COVID still kills people, still hospitalizes people, and still causes lasting symptoms. The emergency is over. The disease is not.
The Virus Keeps Changing
SARS-CoV-2 continues to mutate and produce new variants. The CDC tracks circulating lineages through genomic surveillance, and the landscape shifts constantly. No single variant dominates the way Delta or early Omicron once did. Instead, a patchwork of related lineages circulates simultaneously, with dozens of sub-variants each accounting for small percentages of cases. New variants are expected to keep emerging indefinitely, some replacing others, some fading on their own.
This ongoing evolution is one reason COVID can’t simply be declared “over.” Each new variant carries the potential to partially dodge immunity from previous infections or vaccinations, which is why updated vaccines are released on a schedule similar to the annual flu shot.
Long COVID Remains a Concern
About 10% of people who catch COVID during the current Omicron era develop Long COVID, according to the NIH’s RECOVER study, which prospectively followed over 3,600 adults. That’s lower than in earlier waves, likely because of widespread vaccination and less severe variants, but it’s still a significant number given how many people get infected each year.
Among those who develop Long COVID, the outcomes vary widely. Roughly 46% have persistent symptoms that don’t resolve. Another 35% experience moderate, fluctuating symptoms. About 19% appear to recover within the study’s follow-up period. Perhaps most surprising, 14% of participants who seemed fine at three months developed increasing symptoms by 15 months, suggesting Long COVID can have a delayed onset that catches people off guard.
Vaccines and Treatments in 2025
COVID vaccination has shifted to an annual model. The CDC recommends the 2025-2026 COVID-19 vaccine for everyone ages 6 months and older, with the decision framed as an individual choice rather than a blanket mandate. The recommendation is strongest for people 65 and older, those at high risk for severe illness, residents of long-term care facilities, and pregnant individuals. Anyone who wants to lower their risk of Long COVID is also encouraged to get vaccinated.
If you recently had COVID, you can delay your vaccine by three months from when symptoms started. Multiple vaccine options are available from Moderna, Pfizer-BioNTech, and Novavax.
Antiviral treatment remains available for people at high risk. The oral antiviral nirmatrelvir-ritonavir (commonly known by its brand name Paxlovid) reduces hospitalizations by roughly 53 to 76% in high-risk patients when started early, based on real-world studies during Omicron waves. For people who aren’t at high risk for severe illness, the benefit is less clear. A large clinical trial found no significant difference in how quickly symptoms resolved compared to a placebo in standard-risk patients.
Home Tests Still Work
Rapid antigen tests remain a reliable way to check for COVID. Studies evaluating dozens of test brands against Omicron variants found clinical sensitivity ranging from about 84% to 98%, comfortably meeting international performance standards. The tests are less accurate very early in an infection, so if you test negative but have symptoms, testing again 24 to 48 hours later still makes sense.
Global Gaps Persist
The experience of COVID being “over” depends heavily on where you live. In high-income countries, vaccination rates are high and antiviral treatments are accessible. In low-income nations, the picture is starkly different. Some countries, including Haiti, Papua New Guinea, and Yemen, have vaccinated fewer than 5% of their populations with even a single dose. These gaps mean the virus has large unvaccinated populations in which to circulate and mutate, which has downstream consequences everywhere.
What This Means for Daily Life
For most people in wealthy countries, daily life has returned to something close to pre-pandemic normal. Mask mandates, capacity limits, and widespread closures are gone. But COVID circulates year-round with seasonal peaks, typically in winter and sometimes in late summer. During those surges, hospitals see increased admissions among older adults and immunocompromised individuals.
The practical reality is that COVID has joined the roster of respiratory illnesses you can expect to encounter. You’ll likely catch it more than once over your lifetime. Each infection carries a small but real risk of Long COVID, hospitalization, or worse, particularly if you’re older or have underlying health conditions. Staying current on vaccines, testing when symptomatic, and seeking early treatment if you’re high-risk are the tools that remain relevant. The crisis is over. The virus is permanent.